|
|
9:02:00 AM
 |
Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
PR Newswire
|
| |
Biotechnology industry pioneer Amgen (AMGN), is teaming up with financial software provider BlackLine Systems and enterprise application software leader SAP AG (SAP) for a webinar next week entitled "No Account Left Behind! Learn How Amgen Uses Solutions from BlackLine and SAP to Help Keep Its Account Reconciliations in Good Shape."
|
|
|
12:05:03 PM
|
Soft Tissue Sarcoma - Pipeline Review Market Report, H1 2013 Edition
M2
|
| |
Research and Markets (http://www.researchandmarkets.com/research/fzj8b3/soft_tissue)">http://www.researchandmarkets.com/research/fzj8b3/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2013" report to their offering.
’Soft Tissue Sarcoma - Pipeline Review, H2 2013’, provides an overview of the indication’s therapeutic pipeline.
|
8:00:00 AM
|
Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases -
PR Newswire
|
| |
Today, Wall Street Reports announced new research reports highlighting Amgen Inc. (AMGN), Celgene Corporation (CELG), Vertex Pharmaceuticals Incorporated (VRTX), MannKind Corp.
|
7:30:52 AM
|
Cytokinetics Announces Results From ATOMIC-AHF Will Be Presented At Late Breaking Clinical Trials Se
Thomson Reuters ONE
|
| |
South San Francisco, CA June 18, 2013 - Cytokinetics Incorporated (CYTK) announced today that results from ATOMIC-AHF have been accepted for presentation during a Hot Line Late Breaking Trials Session at the European Society of Cardiology (ESC) Congress 2013.
|
|
|
5:00:32 PM
|
Watch for Amgen to Potentially Pullback After Gaining 1.70% Yesterday
Comtex SmarTrend(R)
|
| |
Amgen (AMGN) traded in a range yesterday that spanned from a low of $98.50 to a high of $100.09.
|
12:42:07 PM
|
Amgen Makes a Move: Up 2.4%
Financial News Network Online
|
| |
Amgen (AMGN), a company whose shares are moving quickly, is trading 2.4% higher to $99.77.
|
12:05:07 PM
|
Amgen Crosses Above its 10-day MA (AMGN)
Financial News Network Online
|
| |
Amgen (AMGN) shares have crossed bullishly above their 10-day moving average of $97.66 on a volume of 1.5 million shares.
|
10:42:52 AM
|
Amgen (AMGN) Approaches New Upside Target of $99.73
Financial News Network Online
|
| |
Shares of Amgen (AMGN) have bullishly opened above the pivot of $97.75 today and have reached the first resistance level of $98.57.
|
4:15:04 AM
|
Nanotechnology Drug Delivery Market in the US 2013 Report
M2
|
| |
Research and Markets (http://www.researchandmarkets.com/research/wslnwg/nanotechnology)">http://www.researchandmarkets.com/research/wslnwg/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering.
Nanotechnology Drug Delivery Market In The Us Expected To Grow At A CAGR Of 84.79 Percent Over The Period 2012-2016
TechNavio’s report, the Nanotechnology Drug Delivery Market in the US 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts.
|
|
|
9:38:02 AM
|
Potential Amgen (AMGN) Trade Targets 20.28% Return
FreshBrewedMedia
|
| |
Amgen Inc (AMGN) closed Thursday’s trading session at $98.51.
|
8:50:29 AM
|
Amgen’s Oncology Drug Meets Primary Endpoint
Zacks.com
|
| |
Amgen (AMGN) recently presented data on its late-stage oncology candidate, trebananib. Results from the phase III global, multicenter, randomized, double-blind, placebo-controlled TRINOVA-1 study showed that trebananib met its primary endpoint of progression-free survival (PFS).
The study is evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in patients with recurrent ovarian cancer.
|
4:45:39 AM
|
FDA approves drug for rare bone condition
McClatchy-Tribune Information Servi
|
| |
An immune-boosting biologic therapy already used to prevent fractures in patients with bone metastases has won the FDA’s approval as a treatment for a rare but painful condition called giant cell tumor of the bone.
The FDA gave an expedited review to Xgeva as an orphan therapy, because its use is expected to benefit a small population of patients. Xgeva is marketed by Thousand Oaks-based Amgen.
Giant cell tumor of the bone most often affects younger adults -- those between 20 and 40 years old -- and is infrequently cancerous. But it can cause unusual fractures and progressive pain, and most commonly occurs in the long bones of the body--the distal femur, proximal tibia and distal radius.
|
4:01:12 AM
|
Amgen receives US FDA’s approval for XGEVA for giant cell tumor of bone, reflecting its first F
M2
|
| |
Biotechnology company Amgen (NasdaqGS:AMGN) revealed on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for a new indication for XGEVA (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (GCTB) following the FDA’s priority review.
|
|
|
7:43:48 PM
|
FDA approves Amgen’s Xgeva for treating rare tumor
McClatchy-Tribune Information Servi
|
| |
The U.S. Food and Drug Administration on Thursday expanded the approved use of Amgen Inc.’s Xgeva for treating giant cell tumor of the bone.
|
3:11:00 PM
|
FDA Approves Amgen’s XGEVA? (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
PR Newswire
|
| |
Amgen (AMGN) today announced that the U.S.
|
10:52:42 AM
|
Global Nanotechnology Drug Delivery Market Report 2013-2016: Market to Grow at a CAGR of 74% over 20
M2
|
| |
Research and Markets (http://www.researchandmarkets.com/research/pg3gn5/global)">http://www.researchandmarkets.com/research/pg3gn5/global) has announced the addition of the "Global Nanotechnology Drug Delivery Market 2012-2016" report to their offering.
IOTA NanoSolutions Ltd., Lena Nanoceutics Ltd., GlaxoSmithKline plc, Celgene Corp., and SkyePharma plc Dominate the Market
Global Nanotechnology Drug Delivery market to grow at a CAGR of 73.97 percent over the period 2012-2016.
|
3:59:43 AM
|
Cancer Diagnostics Partnering Terms and Agreements
M2
|
| |
|
12:40:52 AM
|
Decision Resources Brings Out The Decision Base 2013 Report
Close-Up Media
|
| |
Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, found that the effect of a therapy on key efficacy endpoints, including time to disease progression and overall survival, has the most influence over surveyed U.S.
|
|
|
11:44:02 PM
|
BRIEF: Amgen drug trial sees 34% reduction in ovarian cancer risks
McClatchy-Tribune Information Servi
|
| |
Thousand Oaks-based Amgen announced Wednesday that its trebananib ovarian cancer treatment reduced the risk of disease progression or death by 34 percent in a recent trial.
|
5:09:03 PM
|
Amgen Falls 1.61% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R)
|
| |
Amgen (AMGN) traded in a range yesterday that spanned from a low of $95.97 to a high of $99.50.
|
5:08:33 PM
|
SmarTrend Watching for Potential Rebound in Shares of Amgen After 1.61% Loss
Comtex SmarTrend(R)
|
| |
Amgen (AMGN) traded in a range yesterday that spanned from a low of $95.97 to a high of $99.50.
|
2:06:15 PM
|
Stock Investors Sell Off Shares of Amgen, Down 1.5%
Financial News Network Online
|
| |
Amgen (AMGN), a company whose shares are moving quickly, is trading 1.5% lower to $96.42.
|
12:23:26 PM
|
Infectives Partnering Terms and Agreements Report Contains Over 2,000 Links to Online Copies of Actu
M2
|
| |
Research and Markets (http://www.researchandmarkets.com/research/6qm9f2/infectives)">http://www.researchandmarkets.com/research/6qm9f2/infectives) has announced the addition of the "Infectives Partnering Terms and Agreements" report to their offering.
The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals.
|
9:00:00 AM
|
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovaria
PR Newswire
|
| |
Amgen (AMGN) today announced that the Phase 3 TRINOVA-1 trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS).
|
8:35:00 AM
|
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Me
PR Newswire
|
| |
Amgen (AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced that they will present data from a Phase 2 study evaluating brodalumab, a human monoclonal antibody targeting the IL-17 receptor, being investigated for the treatment of psoriatic arthritis at the 2013 European League Against Rheumatism (EULAR) Annual Meeting in Madrid, June 12-15, 2013.
|
